{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T03:12:55Z","timestamp":1783739575116,"version":"3.55.0"},"reference-count":19,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejso.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Surgical Oncology"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.ejso.2025.111356","type":"journal-article","created":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T17:23:49Z","timestamp":1765473829000},"page":"111356","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Outcome of stage-eligible patients not receiving neoadjuvant chemo-immunotherapy for clinical or procedural reasons: a real practice analysis"],"prefix":"10.1016","volume":"52","author":[{"given":"Cecilia","family":"Pompili","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0645-8026","authenticated-orcid":false,"given":"Pooja","family":"Bhatnagar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katy","family":"Clarke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Franks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshil","family":"Lodhia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Nardini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Otter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2318-8582","authenticated-orcid":false,"given":"Elaine","family":"Teh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Tcherveniakov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Brunelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"19","key":"10.1016\/j.ejso.2025.111356_bib1","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1056\/NEJMoa2311926","article-title":"CheckMate 77T investigators. Perioperative nivolumab in resectable lung cancer","volume":"390","author":"Cascone","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejso.2025.111356_bib2","article-title":"Overall survival with neoadjuvant nivolumab plus chemotherapy in lung cancer","volume":"2","author":"Forde","year":"2025","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.ejso.2025.111356_bib3","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1056\/NEJMoa2302983","article-title":"Perioperative pembrolizumab for early-stage non-small-cell lung cancer","volume":"389","author":"Wakelee","year":"2023","journal-title":"N Engl J Med"},{"issue":"18","key":"10.1016\/j.ejso.2025.111356_bib4","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1056\/NEJMoa2304875","article-title":"Perioperative durvalumab for resectable non-small-cell lung cancer","volume":"389","author":"Heymach","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejso.2025.111356_bib5","series-title":"Nivolumab with chemotherapy for neoadjuvant treatment of resectable non-small-cell lung cancer","year":"2023"},{"key":"10.1016\/j.ejso.2025.111356_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.athoracsur.2014.05.104","article-title":"The society of thoracic surgeons and the European society of thoracic surgeons general thoracic surgery databases: joint standardization of variable definitions and terminology","author":"Fernandez","year":"2015","journal-title":"Ann Thorac Surg"},{"issue":"3","key":"10.1016\/j.ejso.2025.111356_bib7","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.cllc.2024.12.010","article-title":"Surgical and pathological results following neoadjuvant nivolumab and platinum-based chemotherapy for locally advanced resectable NSCLC: a multicentre real-world series from England","volume":"26","author":"Brunelli","year":"2025","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.ejso.2025.111356_bib8","article-title":"Neoadjuvant PD-1 and PD-L1 blockade with chemotherapy for borderline resectable and unresectable stage III non-small cell lung cancer","volume":"22","author":"Ricciuti","year":"2025","journal-title":"JAMA Oncol"},{"issue":"4","key":"10.1016\/j.ejso.2025.111356_bib9","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/j.jtcvs.2024.02.006","article-title":"Treatment patterns and clinical outcomes of patients with resectable non-small cell lung cancer receiving neoadjuvant immunochemotherapy: a large-scale, multicenter, real-world study (NeoR-World)","volume":"168","author":"Yang","year":"2024","journal-title":"J Thorac Cardiovasc Surg"},{"key":"10.1016\/j.ejso.2025.111356_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2025.108618","article-title":"Achieving equitable, timely and comprehensive biomarker testing for patients with NSCLC","volume":"205","author":"Navani","year":"2025","journal-title":"Lung Cancer"},{"key":"10.1016\/j.ejso.2025.111356_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2024.108061","article-title":"An international and multidisciplinary EORTC survey on resectability of stage III non-small cell lung cancer","volume":"199","author":"Houda","year":"2025","journal-title":"Lung Cancer"},{"issue":"6","key":"10.1016\/j.ejso.2025.111356_bib12","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/S1470-2045(18)30261-4","article-title":"Cancer immunotherapy efficacy and patients' sex: a systematic review and meta-analysis","volume":"19","author":"Conforti","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejso.2025.111356_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2022.102394","article-title":"The use of immunotherapy in older patients with advanced non-small cell lung cancer","volume":"106","author":"Tagliamento","year":"2022","journal-title":"Cancer Treat Rev"},{"issue":"21","key":"10.1016\/j.ejso.2025.111356_bib14","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1056\/NEJMoa2202170","article-title":"Investigators. Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer","volume":"386","author":"Forde","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejso.2025.111356_bib15","article-title":"Challenges and controversies in resectable non-small cell lung cancer: a clinician's perspective","volume":"38","author":"Houda","year":"2024","journal-title":"Lancet Reg Health Eur"},{"key":"10.1016\/j.ejso.2025.111356_bib16","doi-asserted-by":"crossref","unstructured":"Patella M, Brunelli A, Adams L, Cafarotti S, Costardi L, De Leyn P, Decaluw\u00e9 H, Franks KN, Fuentes M, Jimenez MF, Karri S, Moons J, Novellis P, Ruffini E, Veronesi G, Voulaz E, Shargall Y. A risk model to predict the delivery of adjuvant chemotherapy following lung resection in patients with pathologically positive lymph nodes. Semin Thorac Cardiovasc Surg 2023 Summer;35(2):387-398.","DOI":"10.1053\/j.semtcvs.2021.12.015"},{"key":"10.1016\/j.ejso.2025.111356_bib17","article-title":"Real-world clinical characteristics, treatment patterns, and clinical outcomes in US patients with stage I-III resected NSCLC without known EGFR mutations: the RESECT study","volume":"6","author":"Gray","year":"2025","journal-title":"Drugs Real World Outcomes"},{"key":"10.1016\/j.ejso.2025.111356_bib18","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.xjon.2022.09.012","article-title":"Intraoperative challenges after induction therapy for non-small cell lung cancer: effect of nodal disease on technical complexity","volume":"12","author":"Feldman","year":"2022","journal-title":"JTCVS Open"},{"issue":"2","key":"10.1016\/j.ejso.2025.111356_bib19","doi-asserted-by":"crossref","first-page":"e306","DOI":"10.1002\/onco.13586","article-title":"Navigating diagnostic and treatment decisions in non-small cell lung cancer: expert commentary on the multidisciplinary team approach","volume":"26","author":"Popat","year":"2021","journal-title":"Oncologist"}],"container-title":["European Journal of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0748798325017846?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0748798325017846?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T02:28:10Z","timestamp":1783736890000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0748798325017846"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":19,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["S0748798325017846"],"URL":"https:\/\/doi.org\/10.1016\/j.ejso.2025.111356","relation":{},"ISSN":["0748-7983"],"issn-type":[{"value":"0748-7983","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Outcome of stage-eligible patients not receiving neoadjuvant chemo-immunotherapy for clinical or procedural reasons: a real practice analysis","name":"articletitle","label":"Article Title"},{"value":"European Journal of Surgical Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejso.2025.111356","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd, BASO ~ The Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"111356"}}